Outlook Therapeutics, Inc.
OTLK · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $1,414 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1,356 | $0 | $0 | $0 |
| Gross Profit | $57 | -$0 | -$0 | -$0 |
| % Margin | 4% | – | – | – |
| R&D Expenses | $27,181 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $39,938 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $67,119 | $0 | $0 | $0 |
| Operating Income | -$67,062 | -$0 | -$0 | -$0 |
| % Margin | -4,744.3% | – | – | – |
| Other Income/Exp. Net | $3,085 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$63,977 | -$0 | -$0 | -$0 |
| Tax Expense | -$1,552 | $0 | $0 | $0 |
| Net Income | -$62,425 | -$0 | -$0 | -$0 |
| % Margin | -4,416.2% | – | – | – |
| EPS | -1.79 | -4.06 | -4.72 | -6.23 |
| % Growth | 55.9% | 14% | 24.2% | – |
| EPS Diluted | -1.79 | -4.06 | -4.72 | -6.23 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | -$90 | $0 | $0 | $0 |
| Interest Expense | $283 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$67,062 | -$0 | -$0 | -$0 |
| % Margin | -4,744.3% | – | – | – |